Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788361 | 0.81 | CYP26A1 (0.49) | TAS1R3TAS1R1CYP26A1L3MBTL1KDM4E | |
| SCHEMBL2079997 | 0.78 | TAS1R3 (0.44) | TAS1R3TAS1R1CYP26A1L3MBTL1ACACB | |
| SCHEMBL10024019 | 0.78 | GAA (0.56) | CTSLTAS1R3TAS1R1CYP26A1L3MBTL1 | |
| SCHEMBL5672076 | 0.78 | GAA (0.56) | CTSLTAS1R3TAS1R1CYP26A1L3MBTL1 | |
| SCHEMBL8054835 | 0.77 | KMT2A (0.47) | TAS1R3TAS1R1CYP26A1ALDH1A1GAA | |
| SCHEMBL8054837 | 0.77 | KMT2A (0.47) | TAS1R3TAS1R1CYP26A1ALDH1A1GAA | |
| SCHEMBL13885653 | 0.76 | LNPEP (0.56) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL12983607 | 0.76 | TAS1R3 (0.52) | TAS1R3TAS1R1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL12983609 | 0.76 | TAS1R3 (0.52) | TAS1R3TAS1R1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL15646784 | 0.76 | XDH (0.51) | CTSLACACBKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CTSL 3649/4885TAS1R3 230/4885TAS1R1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.